Future approaches may involve guiding treatment selection based on metabolic subtypes, such as PFKFB3 inhibitors for glycolysis-dominant heart failure patients or CPT1 agonists for those with lipid metabolism abnormalities (Forte et al., 2024). Here, PFKFB3 is linked to heart failure.